(Total Views: 735)
Posted On: 01/07/2022 3:46:38 AM
Post# of 153941
Article in seeking alpha bullish
Summary
CytoDyn has updated investors on its efforts to push Leronlimab forward on several fronts, including NASH, COVID-19, and HIV.
These programs are moving closer to the finish line and should deliver potent catalysts in the coming years.
Leronlimab continues to deliver impressive results in a multitude of uses and indications.
I used to wonder if Leronlimab could be operative in 30+ indications, but now I am convinced the drug could be a jack of all trades to be employed in some of the hardest to treat populations
Authors conclusion. My Plan
In light of these developments, I am still committed to my previous game plan of increasing the size and frequency of my buy transactions. I have accepted the possibility of these developments nose-dive and do not assist the share price. However, I believe these developments will create subsequent catalysts that are more potent and could lead to a fundamental change for the company.
My time horizon is still several years out to let the company prove their efforts with Leronlimab will be productive, which could radically change the company's valuation and improve investor sentiment.
Summary
CytoDyn has updated investors on its efforts to push Leronlimab forward on several fronts, including NASH, COVID-19, and HIV.
These programs are moving closer to the finish line and should deliver potent catalysts in the coming years.
Leronlimab continues to deliver impressive results in a multitude of uses and indications.
I used to wonder if Leronlimab could be operative in 30+ indications, but now I am convinced the drug could be a jack of all trades to be employed in some of the hardest to treat populations
Authors conclusion. My Plan
In light of these developments, I am still committed to my previous game plan of increasing the size and frequency of my buy transactions. I have accepted the possibility of these developments nose-dive and do not assist the share price. However, I believe these developments will create subsequent catalysts that are more potent and could lead to a fundamental change for the company.
My time horizon is still several years out to let the company prove their efforts with Leronlimab will be productive, which could radically change the company's valuation and improve investor sentiment.
(7)
(0)
